Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain. Its lead product candidate includes injectable meloxicam, a development stage product for the treatment of acute post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine in development stage for the treatment of acute peri-procedural pain; Dex-SL, a product for the treatment of chronic pain; and Fadolmidine, an alpha-2 agonist product candidate administered by injection into the intrathecal space for pain associated with surgery or chronic pain associated with nerve damage to local tissues (neuropathies). It has a license agreement with Orion Corporation for the development and commercialization of Dex and Fadolmidine. The company focuses on offering its products for hospitals and ambulatory care settings primarily in the United States. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
